BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002

 BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics for DF6002

Shots:

  • Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002
  • BMS will be responsible for the development & commercialization of DF6002 and its related products, including strategic decisions, regulatory responsibilities, funding, and manufacturing
  • DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein, currently being evaluated in P-I/II study for patients with advanced solid tumors, which began in Jul’2020. Additionally, BMS plans to advance the research and development of DF6002 in oncology and hematology

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Pharmashots

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post